Halozyme Therapeutics (HALO) Tops Q4 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $124.83 --0%
Revenue Growth %: +37.6%
Financial Fact:
Cost of product sales: 9.13M
Today's EPS Names:
SICP, MNSB, CFFI, More
Revenue Growth %: +37.6%
Financial Fact:
Cost of product sales: 9.13M
Today's EPS Names:
SICP, MNSB, CFFI, More
Join SI Premium – FREE
Halozyme Therapeutics (NASDAQ: HALO) reported Q4 EPS of $0.42, $0.01 better than the analyst estimate of $0.41. Revenue for the quarter came in at $102 million versus the consensus estimate of $100.29 million.
GUIDANCE:
Halozyme Therapeutics sees FY2022 EPS of $2.05-$2.20, versus the consensus of $2.18. Halozyme Therapeutics sees FY2022 revenue of $530-560 million, versus the consensus of $554.2 million.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Spotify (SPOT) Misses Q3 EPS by 36c; misses on guidance
- Pharming Group N.V. (PHAR) Reports Q3 results; offers guidance
- Great Southern Bancorp (GSBC) Misses Q3 EPS by 12c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
